Personalized medicine for patients with MDR-TB

J Antimicrob Chemother. 2016 Apr;71(4):852-5. doi: 10.1093/jac/dkv354. Epub 2015 Oct 27.

Abstract

The emergence of MDR-TB is a cause of great concern due to difficulties in patient management and poor treatment outcomes. Currently the duration of treatment and the choice of drugs for patients with MDR-TB are standardized in many countries. This might not be the best approach since the optimal therapy may depend on different pathogen- and host-related features. Combining the introduction of technological innovations such as whole bacillary genome sequencing for the identification of drug-resistance-associated mutations, therapeutic drug monitoring and host-directed therapies with an individualized approach to MDR-TB management will likely lead to more tolerable, shorter and more efficient treatment regimens and an increase in the quality of life of those affected by MDR-TB.

Publication types

  • Review

MeSH terms

  • Antitubercular Agents / administration & dosage
  • Antitubercular Agents / therapeutic use*
  • Drug Monitoring
  • Humans
  • Mycobacterium tuberculosis
  • Precision Medicine / methods*
  • Tuberculosis, Multidrug-Resistant / diagnosis
  • Tuberculosis, Multidrug-Resistant / drug therapy*

Substances

  • Antitubercular Agents